查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914715

肝癌藥物市場－全球產業規模、佔有率、趨勢、機會及預測（依癌症類型、器材、年齡、病因、給藥途徑、通路、地區及競爭格局分類，2021-2031年）

Liver Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Cancer Type, By Equipment, By Age, By Factors, By Route of Administration, By Distribution channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肝癌治療市場預計將從2025年的41.1億美元成長到2031年的69.4億美元，複合年成長率（CAGR）為9.12%。該市場涵蓋多種藥物干預措施，包括標靶治療、免疫療法和化療藥物，旨在治療肝細胞癌和肝內膽管癌。推動市場成長的關鍵因素包括全球慢性B型和C型肝炎發病率的上升，以及與METABOLIC INC.症候群相關的非酒精性脂肪肝盛行率的增加。此外，不斷上漲的醫療保健成本和人口老化也支撐了對先進臨床解決方案的強勁需求，確保市場成長超越短期趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 41.1億美元
市場規模：2031年 69.4億美元
複合年成長率：2026-2031年 9.12%
成長最快的細分市場 標靶治療
最大的市場 北美洲

然而，創新生物療法和聯合治療的高昂成本嚴重阻礙了市場成長，限制了患者的治療機會，尤其是在開發中國家。晚期診斷的高發生率進一步加劇了這一經濟挑戰，限制了治療性介入的效用，並給醫療預算帶來了巨大壓力。根據美國癌症協會預測，到2024年，全球將有超過70萬人死於肝癌。這項數據凸顯了開發經濟有效的治療方法以應對該疾病高死亡率的迫切需求。

市場促進因素

市場擴張的根本驅動力在於慢性B型和C型肝炎病毒感染帶來的巨大負擔，這兩種病毒感染是全球肝細胞癌的主要原因。隨著慢性病毒性肝炎進展為肝硬化和惡性腫瘤，需要持續長期管理和藥物干預，這直接推動了對病毒和抗腫瘤治療的需求。世界衛生組織（世衛組織）於2024年4月發布的《2024年世界肝炎報告》顯示，到2022年，全球將有約2.54億慢性乙型肝炎患者和5000萬慢性丙型肝炎患者，這凸顯了龐大的患者群體需要疾病修正治療和後續觀察。

同時，新型免疫療法和聯合治療的加速應用正在重塑該領域，這些療法已顯著超越傳統全身療法，成為不可切除疾病的標準治療方案。製藥公司正積極將能夠延長患者生存期的查核點抑制劑商業化，其在已開發市場的應用也迅速成長。例如，Astra Zeneca在2024年11月發布的「2024年第三季財報」中報告稱，其免疫療法Imfinzi的第三季銷售額達到16億美元，較去年同期成長31%，這主要得益於腫瘤領域的需求成長。生物製藥使用量的激增與癌症診斷率的持續上升相吻合。根據美國癌症協會發布的《2024年癌症事實與數據》，預計2024年美國將新增41,630例肝癌和肝內膽管癌病例，凸顯了對這些先進治療方法的迫切需求。

市場挑戰

生物製藥和聯合治療帶來的巨大經濟負擔是全球肝癌治療市場的主要阻礙因素。高昂的藥物研發和生產成本最終會推高終端使用者的治療費用，限制病患的用藥途徑，尤其是在醫療報銷體系薄弱的發展中地區。當價格超出公共衛生預算和患者的負擔能力時，治療方法的普及率會顯著下降。這種經濟障礙阻礙了臨床解決方案的廣泛應用，最終減少了生產商的潛在收入來源，並抑制了市場擴張。

高昂的單次治療費用以及疾病的高發生率加劇了這項挑戰。市場面臨高發病率帶來的高需求與大規模治療經濟可行性低之間的權衡。根據美國癌症協會估計，2024年美國將新增約41,630例肝癌病例。使用昂貴的治療藥物治療如此多的患者，累積費用將給保險公司和國家醫療保健系統帶來沉重負擔。因此，支付方通常會實施嚴格的報銷標準，這限制了潛在市場規模，並阻礙了整個產業的成長。

市場趨勢

局部治療與全身性治療的融合正在迅速改變肝細胞癌（HCC）的治療格局，尤其對於傳統上僅採用導管介入治療的過渡時期HCC患者而言更是如此。這一趨勢是將全身性免疫療法與經動脈化療栓塞術（TACE）直接整合，以降低單純栓塞治療的高復發率。透過在治療早期引入生物製藥，臨床醫生旨在靶向微轉移病灶並改善長期療效。根據2025年1月《柳葉刀》雜誌報道，EMERALD-1試驗結果顯示，Durvalumab、Bevacizumab聯合治療TACE治療的中位無惡化生存期達到15.0個月，與標準TACE通訊協定相比，療效具有統計學意義的顯著改善，有效擴大了先進治療方法的應用範圍。

同時，新一代口服蛋白酪氨酸激酶抑制劑（TKI）市場正在經歷復興和發展，尤其是在新型聯合治療策略方面，其療效樹立了新的標竿。與傳統的全身性治療不同，這些現代小分子抑制劑與查核點抑制劑合併使用時，能夠顯著延長患者的存活期，突破傳統臨床治療在不可切除疾病中的限制。這一趨勢凸顯了激酶抑制劑作為治療平台的重要性。根據《美國臨床腫瘤學會郵報》（The ASCO Post）2025年10月報道，在CARES-310試驗的最終分析中，蛋白酪氨酸激酶抑製劑利沃塞拉尼（rivocelanib）與卡瑞利珠單抗（camrelizumab）的聯合治療治療方法顯示出23.8個月的中位總生存期。這是目前國際III期臨床試驗中針對此適應症通報的最長總存活期，進一步證實了標靶口服藥物的重新運作。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球肝癌治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依癌症類型（肝細胞癌、膽管癌、肝轉移瘤、肝母細胞瘤、血管肉瘤）
    • 治療方法（標靶治療、放射線治療和化療、免疫治療、其他）
    • 透過設備（電腦放射成像、磁振造影、超音波、其他）
    • 依年齡分類（0-18歲、18-35歲、35-50歲、50歲以上）
    • 依病因分類（非酒精性脂肪肝、肝硬化、肝臟過度消耗、其他）
    • 給藥途徑（口服、靜脈注射、其他）
    • 通路（醫院藥房、零售藥房、網路藥房）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肝癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肝癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章 亞太地區肝癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肝癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肝癌藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球肝癌藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bayer AG
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • AstraZeneca PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4667

The Global Liver Cancer Therapeutics Market is projected to expand from USD 4.11 Billion in 2025 to USD 6.94 Billion by 2031, reflecting a CAGR of 9.12%. This market encompasses pharmacological interventions, including targeted therapies, immunotherapies, and chemotherapeutic agents, designed to treat hepatocellular carcinoma and intrahepatic bile duct cancers. Growth is primarily driven by the rising global incidence of chronic Hepatitis B and C infections, along with the increasing prevalence of non-alcoholic fatty liver disease linked to metabolic syndromes. Furthermore, increased healthcare expenditure and an aging population are supporting robust demand for advanced clinical solutions, ensuring growth beyond temporary trends.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.11 Billion
Market Size 2031USD 6.94 Billion
CAGR 2026-20319.12%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Conversely, the substantial costs associated with innovative biologic treatments and combination regimens present a major obstacle to market growth, restricting patient access particularly in developing economies. This economic challenge is compounded by the high frequency of late-stage diagnoses, which limits the utility of curative interventions and strains healthcare budgets. According to the American Cancer Society, liver cancer caused over 700,000 deaths globally in 2024. This statistic highlights the urgent necessity for cost-effective therapeutic advancements to address the high mortality rates associated with the disease.

Market Driver

The market's expansion is fundamentally propelled by the significant burden of chronic Hepatitis B and C viral infections, which act as the leading causes of hepatocellular carcinoma worldwide. As chronic viral hepatitis progresses to liver cirrhosis and malignancy, it creates a continuous need for long-term management and pharmacological intervention, directly driving the demand for antiviral and antineoplastic treatments. According to the World Health Organization's 'Global Hepatitis Report 2024' released in April 2024, approximately 254 million people were living with chronic hepatitis B and 50 million with hepatitis C globally in 2022, underscoring the vast population requiring disease-modifying therapies and surveillance.

Simultaneously, the sector is being reshaped by the accelerated adoption of novel immunotherapy and combination regimens, which have largely superseded older systemic agents as the standard of care for unresectable disease. Pharmaceutical developers are actively commercializing checkpoint inhibitors that offer superior survival rates, leading to rapid uptake in developed economies. For instance, AstraZeneca reported in its 'Q3 2024 Results' in November 2024 that the immunotherapy agent Imfinzi generated $1.6 billion in sales in the third quarter alone, a 31% year-over-year increase driven by oncology demand. This surge in biologic utilization coincides with persistent diagnostic rates; the American Cancer Society's 'Cancer Facts & Figures 2024' projected 41,630 new cases of liver and intrahepatic bile duct cancer in the US for the year, reinforcing the critical need for these advanced options.

Market Challenge

The significant financial burden associated with biologic treatments and combination regimens serves as a primary restraint on the global liver cancer therapeutics market. High drug development and manufacturing expenses result in elevated pricing for end users, which limits patient access, particularly in developing regions with inadequate healthcare reimbursement frameworks. When pharmacological interventions are priced beyond the reach of public health budgets and individual patients, adoption rates slow considerably. This economic barrier prevents the widespread utilization of clinical solutions, thereby reducing potential revenue streams for manufacturers and stalling market expansion.

This challenge is further compounded when the high cost per patient is multiplied by the significant prevalence of the disease. The market faces a dichotomy where demand is robust due to incidence rates, yet the economic feasibility for widespread treatment remains low. According to the American Cancer Society, an estimated 41,630 new cases of liver cancer were diagnosed in the United States in 2024. The cumulative cost required to treat such a volume of patients with premium-priced therapeutics places immense pressure on insurance providers and national health systems. Consequently, payers often implement strict reimbursement criteria, which limits the addressable market size and hampers the overall growth trajectory of the industry.

Market Trends

The Convergence of Locoregional and Systemic Therapies is rapidly transforming the treatment landscape, specifically for patients with intermediate-stage hepatocellular carcinoma who were historically managed with catheter-based interventions alone. This trend involves the integration of systemic immunotherapies directly with transarterial chemoembolization (TACE) to reduce the high rates of disease recurrence associated with embolization monotherapy. By introducing biologic agents earlier in the treatment continuum, clinicians aim to target micrometastatic disease and improve long-term outcomes. According to The Lancet in January 2025, the 'EMERALD-1 study results' showed that the combination of durvalumab, bevacizumab, and TACE achieved a median progression-free survival of 15.0 months, a statistically significant improvement over the standard TACE protocol, effectively expanding the utilization of advanced therapeutics.

Simultaneously, the market is witnessing the resurgence and evolution of Next-Generation Oral Tyrosine Kinase Inhibitors (TKIs), which are establishing new efficacy benchmarks particularly when utilized in novel combination strategies. Unlike legacy systemic agents, these modern small molecule inhibitors are being paired with checkpoint inhibitors to deliver extended survival benefits that challenge historical clinical ceilings in unresectable disease. This trend highlights the continued relevance of kinase inhibitors as a cornerstone of therapy. According to The ASCO Post in October 2025, the 'CARES-310 trial final analysis' reported that the combination of the tyrosine kinase inhibitor rivoceranib and camrelizumab demonstrated a median overall survival of 23.8 months, the longest duration reported for any treatment in a global Phase 3 study for this indication, underscoring the revitalized role of targeted oral agents.

Key Market Players

  • Bayer AG
  • Bristol Myers Squibb
  • Merck & Co., Inc.
  • Exelixis, Inc.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Eli Lilly and Company
  • Novartis AG
  • AstraZeneca PLC

Report Scope

In this report, the Global Liver Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liver Cancer Therapeutics Market, By Cancer Type

  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Liver Metastasis
  • Hepatoblastoma
  • Angiosarcoma

Liver Cancer Therapeutics Market, By Therapy

  • Targeted Therapy
  • Radiation and Chemotherapy Therapy
  • Immunotherapy
  • Others

Liver Cancer Therapeutics Market, By Equipment

  • Computed Radiography
  • MRI
  • Sonography
  • Others

Liver Cancer Therapeutics Market, By Age

  • 0-18
  • 18-35
  • 35-50
  • 50+

Liver Cancer Therapeutics Market, By Factors

  • Non-Alcoholic Fatty Liver Disease
  • Cirrhosis
  • Excessive Liver Consumption
  • Others

Liver Cancer Therapeutics Market, By Route of Administration

  • Oral
  • Intra-Venous
  • Others

Liver Cancer Therapeutics Market, By Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Liver Cancer Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liver Cancer Therapeutics Market.

Available Customizations:

Global Liver Cancer Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Liver Cancer Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Liver Metastasis, Hepatoblastoma, Angiosarcoma)
    • 5.2.2. By Therapy (Targeted Therapy, Radiation and Chemotherapy Therapy, Immunotherapy, Others)
    • 5.2.3. By Equipment (Computed Radiography, MRI, Sonography, Others)
    • 5.2.4. By Age (0-18, 18-35, 35-50, 50+)
    • 5.2.5. By Factors (Non-Alcoholic Fatty Liver Disease, Cirrhosis, Excessive Liver Consumption, Others)
    • 5.2.6. By Route of Administration (Oral, Intra-Venous, Others)
    • 5.2.7. By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.8. By Region
    • 5.2.9. By Company (2025)
  • 5.3. Market Map

6. North America Liver Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type
    • 6.2.2. By Therapy
    • 6.2.3. By Equipment
    • 6.2.4. By Age
    • 6.2.5. By Factors
    • 6.2.6. By Route of Administration
    • 6.2.7. By Distribution channel
    • 6.2.8. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Liver Cancer Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Cancer Type
        • 6.3.1.2.2. By Therapy
        • 6.3.1.2.3. By Equipment
        • 6.3.1.2.4. By Age
        • 6.3.1.2.5. By Factors
        • 6.3.1.2.6. By Route of Administration
        • 6.3.1.2.7. By Distribution channel
    • 6.3.2. Canada Liver Cancer Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Cancer Type
        • 6.3.2.2.2. By Therapy
        • 6.3.2.2.3. By Equipment
        • 6.3.2.2.4. By Age
        • 6.3.2.2.5. By Factors
        • 6.3.2.2.6. By Route of Administration
        • 6.3.2.2.7. By Distribution channel
    • 6.3.3. Mexico Liver Cancer Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Cancer Type
        • 6.3.3.2.2. By Therapy
        • 6.3.3.2.3. By Equipment
        • 6.3.3.2.4. By Age
        • 6.3.3.2.5. By Factors
        • 6.3.3.2.6. By Route of Administration
        • 6.3.3.2.7. By Distribution channel

7. Europe Liver Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapy
    • 7.2.3. By Equipment
    • 7.2.4. By Age
    • 7.2.5. By Factors
    • 7.2.6. By Route of Administration
    • 7.2.7. By Distribution channel
    • 7.2.8. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Liver Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Equipment
        • 7.3.1.2.4. By Age
        • 7.3.1.2.5. By Factors
        • 7.3.1.2.6. By Route of Administration
        • 7.3.1.2.7. By Distribution channel
    • 7.3.2. France Liver Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Equipment
        • 7.3.2.2.4. By Age
        • 7.3.2.2.5. By Factors
        • 7.3.2.2.6. By Route of Administration
        • 7.3.2.2.7. By Distribution channel
    • 7.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Equipment
        • 7.3.3.2.4. By Age
        • 7.3.3.2.5. By Factors
        • 7.3.3.2.6. By Route of Administration
        • 7.3.3.2.7. By Distribution channel
    • 7.3.4. Italy Liver Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Equipment
        • 7.3.4.2.4. By Age
        • 7.3.4.2.5. By Factors
        • 7.3.4.2.6. By Route of Administration
        • 7.3.4.2.7. By Distribution channel
    • 7.3.5. Spain Liver Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Equipment
        • 7.3.5.2.4. By Age
        • 7.3.5.2.5. By Factors
        • 7.3.5.2.6. By Route of Administration
        • 7.3.5.2.7. By Distribution channel

8. Asia Pacific Liver Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapy
    • 8.2.3. By Equipment
    • 8.2.4. By Age
    • 8.2.5. By Factors
    • 8.2.6. By Route of Administration
    • 8.2.7. By Distribution channel
    • 8.2.8. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Liver Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Equipment
        • 8.3.1.2.4. By Age
        • 8.3.1.2.5. By Factors
        • 8.3.1.2.6. By Route of Administration
        • 8.3.1.2.7. By Distribution channel
    • 8.3.2. India Liver Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Equipment
        • 8.3.2.2.4. By Age
        • 8.3.2.2.5. By Factors
        • 8.3.2.2.6. By Route of Administration
        • 8.3.2.2.7. By Distribution channel
    • 8.3.3. Japan Liver Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Equipment
        • 8.3.3.2.4. By Age
        • 8.3.3.2.5. By Factors
        • 8.3.3.2.6. By Route of Administration
        • 8.3.3.2.7. By Distribution channel
    • 8.3.4. South Korea Liver Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Equipment
        • 8.3.4.2.4. By Age
        • 8.3.4.2.5. By Factors
        • 8.3.4.2.6. By Route of Administration
        • 8.3.4.2.7. By Distribution channel
    • 8.3.5. Australia Liver Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Equipment
        • 8.3.5.2.4. By Age
        • 8.3.5.2.5. By Factors
        • 8.3.5.2.6. By Route of Administration
        • 8.3.5.2.7. By Distribution channel

9. Middle East & Africa Liver Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapy
    • 9.2.3. By Equipment
    • 9.2.4. By Age
    • 9.2.5. By Factors
    • 9.2.6. By Route of Administration
    • 9.2.7. By Distribution channel
    • 9.2.8. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Liver Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Equipment
        • 9.3.1.2.4. By Age
        • 9.3.1.2.5. By Factors
        • 9.3.1.2.6. By Route of Administration
        • 9.3.1.2.7. By Distribution channel
    • 9.3.2. UAE Liver Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Equipment
        • 9.3.2.2.4. By Age
        • 9.3.2.2.5. By Factors
        • 9.3.2.2.6. By Route of Administration
        • 9.3.2.2.7. By Distribution channel
    • 9.3.3. South Africa Liver Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Equipment
        • 9.3.3.2.4. By Age
        • 9.3.3.2.5. By Factors
        • 9.3.3.2.6. By Route of Administration
        • 9.3.3.2.7. By Distribution channel

10. South America Liver Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapy
    • 10.2.3. By Equipment
    • 10.2.4. By Age
    • 10.2.5. By Factors
    • 10.2.6. By Route of Administration
    • 10.2.7. By Distribution channel
    • 10.2.8. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Equipment
        • 10.3.1.2.4. By Age
        • 10.3.1.2.5. By Factors
        • 10.3.1.2.6. By Route of Administration
        • 10.3.1.2.7. By Distribution channel
    • 10.3.2. Colombia Liver Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Equipment
        • 10.3.2.2.4. By Age
        • 10.3.2.2.5. By Factors
        • 10.3.2.2.6. By Route of Administration
        • 10.3.2.2.7. By Distribution channel
    • 10.3.3. Argentina Liver Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Equipment
        • 10.3.3.2.4. By Age
        • 10.3.3.2.5. By Factors
        • 10.3.3.2.6. By Route of Administration
        • 10.3.3.2.7. By Distribution channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Liver Cancer Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bayer AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bristol Myers Squibb
  • 15.3. Merck & Co., Inc.
  • 15.4. Exelixis, Inc.
  • 15.5. Eisai Co., Ltd.
  • 15.6. F. Hoffmann-La Roche Ltd
  • 15.7. Pfizer Inc.
  • 15.8. Eli Lilly and Company
  • 15.9. Novartis AG
  • 15.10. AstraZeneca PLC

16. Strategic Recommendations

17. About Us & Disclaimer